ACH
ALDR

ArrowMark Colorado Holdings’s Alder Biopharmaceuticals ALDR Stock Holding History

ArrowMark Colorado Holdings’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-18,082
Closed -$222K – 354
2017
Q3 		$222K Sell
18,082
-1,568
-8% -$16.3K ﹤0.01% 325
2017
Q2 		$225K Sell
19,650
-1,450
-7% -$26.8K ﹤0.01% 311
2017
Q1 		$439K Buy
21,100
+100
+0.5% +$2.21K 0.01% 277
2016
Q4 		$437K Buy
21,000
+468
+2% +$12.2K 0.01% 273
2016
Q3 		$673K Hold
20,532
– – 0.01% 244
2016
Q2 		$513K Hold
20,532
– – 0.01% 247
2016
Q1 		$503K Sell
20,532
-1,100
-5% -$25.5K 0.01% 240
2015
Q4 		$715K Hold
21,632
– – 0.02% 233
2015
Q3 		$709K Sell
21,632
-808
-4% -$34.4K 0.02% 237
2015
Q2 		$1.19M Sell
22,440
-4,810
-18% -$175K 0.03% 229
2015
Q1 		$786K Buy
+27,250
New +$748K 0.02% 228

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

ArrowMark Colorado Holdings's ALDR Position: Q4 2017 in Review

ArrowMark Colorado Holdings sold out of Alder Biopharmaceuticals (ALDR) in Q4 2017, closing a stake of 18,082 shares — an estimated $222K sold.

ArrowMark Colorado Holdings first reported a position in ALDR in Q1 2015 and held it in 11 quarters. The position peaked at $1.19M in Q2 2015. 140 funds tracked by Wall St. Rank hold ALDR as of Q4 2017.

  • ArrowMark Colorado Holdings reported no remaining Alder Biopharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • ArrowMark Colorado Holdings sold 18,082 Alder Biopharmaceuticals shares in Q4 2017, an estimated $222K.
  • ArrowMark Colorado Holdings first reported a position in Alder Biopharmaceuticals in Q1 2015 and held it in 11 quarters.
  • ArrowMark Colorado Holdings's Alder Biopharmaceuticals position peaked at $1.19M in Q2 2015.
  • 140 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2017.

Based on ArrowMark Colorado Holdings's 13F filing for Q4 2017, filed 14 Feb 2018.